The Tumor Lysis Syndrome
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
The tumor lysis syndrome is the most common disease-related emergency in children and adults with hematologic cancers. This review summarizes current strategies for risk assessment, prophylaxis, and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An important consideration with respect to safety in patients that may have a compromised immune system is that engineered bacterial products are likely to engage both innate and adaptive immunity in the event of release of the organism into the body following tumor lysis75, triggering inflammatory responses.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [75]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Uric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
Intensity of Renal Support in Critically Ill Patients with Acute Kidney Injury
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802639 · Cited by 1,759
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
Pui, C.-H., Campana, D., Pei, D., Bowman, W. P., Sandlund, J. T., Kaste, S. C., Ribeiro, R. C., Rubnitz, J. E., Raimondi, S. C., Onciu, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900386 · Cited by 1,215
Self-citationTumour lysis syndrome: new therapeutic strategies and classification
Cairo, M. S., & Bishop, M. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05094.x · Cited by 1,076
Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
Coiffier, B., Altman, A., Pui, C.-H., Younes, A., & Cairo, M. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0177 · Cited by 792
Self-citationCairo, M. S., Coiffier, B., Reiter, A., Younes, A., & Panel, O. B. O. T. T. E. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08143.x · Cited by 570
Goldman, S. C., Holcenberg, J. S., Finklestein, J. Z., Hutchinson, R., Kreissman, S., Johnson, F. L., Tou, C., Harvey, E., Morris, E., & Cairo, M. S. (2001) · Blood · doi:10.1182/blood.v97.10.2998 · Cited by 477
Cairo, M. S., Gerrard, M., Sposto, R., Auperin, A., Pinkerton, C. R., Michon, J., Weston, C., Perkins, S. L., Raphael, M., McCarthy, K., et al. (2007) · Blood · doi:10.1182/blood-2006-07-036665 · Cited by 363
Pui, C.-H., Mahmoud, H. H., Wiley, J. M., Woods, G. M., Leverger, G., Camitta, B., Hastings, C., Blaney, S. M., Relling, M. V., & Reaman, G. H. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.697 · Cited by 361
Self-citationOral Phosphate Binders in Patients with Kidney Failure
Tonelli, M., Pannu, N., & Manns, B. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912522 · Cited by 339
Physicochemical aspects of urolithiasis
Finlayson, B. (1978) · Kidney International · doi:10.1038/ki.1978.53 · Cited by 312
Improving Outcomes From Acute Kidney Injury: Report of an Initiative
Levin, A., Warnock, D. G., Mehta, R. L., Kellum, J. A., Shah, S. V., Molitoris, B. A., & Ronco, C. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.05.008 · Cited by 259
Coiffier, B., Mounier, N., Bologna, S., Fermé, C., Tilly, H., Sonet, A., Christian, B., Casasnovas, O., Jourdan, E., Belhadj, K., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.115 · Cited by 237
Montesinos, P., Lorenzo, I., Martin, G., Sanz, J., Perez-Sirvent, M. L., Martinez, D., Orti, G., Algarra, L., Martinez, J., Moscardo, F., et al. (2008) · Haematologica · doi:10.3324/haematol.11575 · Cited by 231
Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules
Wesson, J. A., Worcester, E. M., Wiessner, J. H., Mandel, N. S., & Kleinman, J. G. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00839.x · Cited by 202
Cortes, J., Moore, J. O., Maziarz, R. T., Wetzler, M., Craig, M., Matous, J., Luger, S., Dey, B. R., Schiller, G. J., Pham, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.8896 · Cited by 196
Could Uric Acid Have a Role in Acute Renal Failure?
Ejaz, A. A., Mu, W., Kang, D.-H., Roncal, C., Sautin, Y. Y., Henderson, G., Tabah-Fisch, I., Keller, B., Beaver, T. M., Nakagawa, T., et al. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00350106 · Cited by 187
Jeha, S., Kantarjian, H., Irwin, D., Shen, V, Shenoy, S., Blaney, S., Camitta, B., & Pui, C.-H. (2005) · Leukemia · doi:10.1038/sj.leu.2403566 · Cited by 181
Self-citationSundy, J. S., Becker, M. A., Baraf, H. S. B., Barkhuizen, A., Moreland, L. W., Huang, W., Waltrip, R. W., Maroli, A. N., Horowitz, Z., & Pegloticase Phase 2 Study Investigators (2008) · Arthritis & Rheumatism · doi:10.1002/art.23810 · Cited by 181
Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies
Pui, C.-H., Relling, M., Lascombes, F., Harrison, P., Struxiano, A., Mondesir, J.-M., Ribeiro, R., Sandlund, J., Rivera, G., Evans, W., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400850 · Cited by 174
Self-citationBowman, W. P., Shuster, J. J., Cook, B., Griffin, T., Behm, F., Pullen, J., Link, M., Head, D., Carroll, A., Berard, C., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.4.1252 · Cited by 166
Urinary Xanthine Stones-a Rare Complication of Allopurinol Therapy
Greene, M. L., Fujimoto, W. Y., & Seegmiller, J. E. (1969) · New England Journal of Medicine · doi:10.1056/nejm196902202800806 · Cited by 165
Bosly, A., Sonet, A., Pinkerton, R., McCowage, G. B., Bron, D., Sanz, M. Á., & den Berg, H. V. (2003) · Cancer · doi:10.1002/cncr.11612 · Cited by 163
Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy.
Conger, J. D., & Falk, S. A. (1977) · Journal of Clinical Investigation · doi:10.1172/jci108700 · Cited by 156
Pui, C., Jeha, S., Irwin, D. H., & Camitta, B. M. (2001) · Leukemia · doi:10.1038/sj.leu.2402235 · Cited by 151
Self-citationA novel role for uric acid in acute kidney injury associated with tumour lysis syndrome
Shimada, M., Johnson, R., May, W. S., Lingegowda, V., Sood, P., Nakagawa, T., Van, Q. C., Dass, B., & Ejaz, A. A. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp330 · Cited by 136
Tumor Lysis Syndrome and Acute Kidney Injury: Evaluation, Prevention, and Management
Abu‐Alfa, A. K., & Younes, A. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.10.056 · Cited by 135
Genetic Disorders of Renal Phosphate Transport
Prié, D., & Friedlander, G. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0904186 · Cited by 110
Patte, C., Sakiroglu, C., Ansoborlo, S., Baruchel, A., Plouvier, E., Pacquement, H., & Babin-Boilletot, A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf134 · Cited by 95
Estimating phosphate removal in haemodialysis: an additional tool to quantify dialysis dose
Gutzwiller, J., Schneditz, D., Huber, A. R., Schindler, C., Gutzwiller, F., & Zehnder, C. E. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.6.1037 · Cited by 88
Acute renal failure from xanthine nephropathy during management of acute leukemia
LaRosa, C. J., McMullen, L., Bakdash, S., Ellis, D., Krishnamurti, L., Wu, H., & Moritz, M. L. (2006) · Pediatric Nephrology · doi:10.1007/s00467-006-0287-z · Cited by 86
A predictive model for the detection of tumor lysis syndrome during AML induction therapy
Mato, A. R., Riccio, B. E., Li, Q., Heitjan, D. F., Carroll, M. P., Loren, A. W., Porter, D., Perl, A. E., Stadtmauer, E. A., Tsai, D. E., et al. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500404662 · Cited by 84
Tan, H. K., Bellomo, R., M’Pisi, D. A., & Ronco, C. (2001) · The International Journal of Artificial Organs · doi:10.1177/039139880102400403 · Cited by 65
Soares, M., Feres, G. A., & Salluh, J. I. (2009) · Clinics · doi:10.1590/s1807-59322009000500016 · Cited by 58
Pais, V. M., Lowe, G. F., Lallas, C. D., Preminger, G. M., & Assimos, D. G. (2006) · Urology · doi:10.1016/j.urology.2005.10.057 · Cited by 56
Truong, T. H., Beyene, J., Hitzler, J. K., Abla, O., Maloney, A. M., Weitzman, S. S., & Sung, L. (2007) · Cancer · doi:10.1002/cncr.22990 · Cited by 52
Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient
Huang, W.-S., & Yang, C.-H. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.4464 · Cited by 52
Cetuximab-Related Tumor Lysis Syndrome in Metastatic Colon Carcinoma
Krishnan, G., D'Silva, K. J., & Al-Janadi, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7603 · Cited by 47
Hijiya, N., Metzger, M. L., Pounds, S. B., Schmidt, J. E., Razzouk, B. I., Rubnitz, J. E., Howard, S. C., Núnêz, C., Pui, C., & Ribeiro, R. C. (2004) · Pediatric Blood & Cancer · doi:10.1002/pbc.20192 · Cited by 42
Self-citationJeddi, R., Abdennebi, Y. B., Allani, B., Belakhal, R., Aissaouï, L., Abid, H. B., Ali, Z. B. H., & Meddeb, B. (2007) · PubMed · Cited by 41
Nakamura, M., Oda, S., Sadahiro, T., Hirayama, Y., Tateishi, Y., Abe, R., & Hirasawa, H. (2008) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2008.11.004 · Cited by 38
Fatal Tumor Lysis Syndrome During Radiotherapy for Non–Small-Cell Lung Cancer
Noh, G. Y., Choe, D. H., Kim, C. H., & Lee, J. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.4308 · Cited by 38
Emerging drugs for hyperphosphatemia
Bellinghieri, G., Santoro, D., & Savica, V. (2007) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.12.3.355 · Cited by 37
Effects of Urinary Macromolecules on Hydroxyapatite Crystal Formation
Beshensky, A. M., Wesson, J. A., Worcester, E. M., SOROKINA, E. J., SNYDER, C. J., & Kleinman, J. G. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v12102108 · Cited by 37
A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults
Giráldez, M., & Puto, K. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01457.x · Cited by 33
Uric acid as inducer of calcium oxalate crystal development
Grases, F., Sanchís, P., Isern, B., Perelló, J., & Costa‐Bauzá, A. (2006) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/00365590600831571 · Cited by 33
Knoebel, R. W., Lo, M., & Crank, C. W. (2010) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155210364180 · Cited by 33
Joshita, S., Yoshizawa, K., Sano, K., Kobayashi, S., Sekiguchi, T., Morita, S., Kamijo, A., Komatsu, M., Umemura, T., Ichijo, T., et al. (2010) · Internal Medicine · doi:10.2169/internalmedicine.49.3153 · Cited by 31
Rasburicase: future directions in tumor lysis management
Hochberg, J. C., & Cairo, M. S. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.10.1595 · Cited by 26
Managing tumor lysis syndrome in 2010
Gertz, M. A. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190903488788 · Cited by 21
Growth of calcium oxalate monohydrate on uric acid crystals at sustained supersaturation
Bouropoulos, C., Vagenas, N., Klepetsanis, P. G., Stavropoulos, N., & Bouropoulos, N. (2004) · Crystal Research and Technology · doi:10.1002/crat.200310241 · Cited by 21
Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia.
Cheson, B. D. (2009) · PubMed · Cited by 20
Godoy, H. E., Kesterson, J. P., & Lele, S. (2010) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2010.02.005 · Cited by 19
Management of Tumor Lysis Syndrome: Need for Evidence-Based Guidelines
Feusner, J. H., Ritchey, A. K., Cohn, S. L., & Billett, A. L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6030 · Cited by 19
Pitfalls in predicting tumor lysis syndrome
Howard, S. C., & Pui, C. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190600765798 · Cited by 16
Self-citationHoward, S. C., Ribeiro, R. C., & Pui, C. (2006) · Cambridge University Press eBooks · doi:10.1017/cbo9780511471001.030 · Cited by 12
Self-citationTumor Lysis Syndrome in Solid Tumors
Gemici, C. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4154 · Cited by 11
Magrath, I. T., Semawere, C., & Nkwocha, J. (1974) · PubMed · Cited by 10
Catastrophic tumour lysis syndrome following single dose of imatinib
Keane, C., Henden, A. S., & Bird, R. J. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01186.x · Cited by 9
Cited by
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
DiNardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2012971 · Cited by 2,900
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,900
“Chromosome 17p deletion 19/49 (39) 12/53 (23) 31/102 (30)”
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M., Montserrat, E., Chiorazzi, N., et al. (2018) · Blood · doi:10.1182/blood-2017-09-806398 · Cited by 1,740
Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H. J., Schlößer, H. A., Schlaak, M., Kochanek, M., Böll, B., & von Bergwelt-Baildon, M. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0343-9 · Cited by 1,656
“Although tumor lysis syndrome usually can be readily discriminated from CRS on the basis of characteristic laboratory abnormalities such as hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia, it can sometimes be difficult to determine if CRS and tumor lysis syndrome occur concurrently [46].”
BackgroundVenetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
Fischer, K., Al-Sawaf, O., Bahlo, J., Fink, A.-M., Tandon, M., Dixon, M., Robrecht, S., Warburton, S., Humphrey, K., Samoylova, O., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815281 · Cited by 873
Metadata
- Authors
- Howard, S. C., Jones, D. P., & Pui, C.-H.
- Affiliations
- St. Jude Children's Research Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-05-12
- Volume
- 364
- Issue
- 19
- Pages
- 1844-1854
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3437249
- OpenAlex
- W2122479144
- Cited by
- 1,044
- References
- 58
- Citations by year
- 2026: 71 · 2025: 67 · 2024: 86 · 2023: 71 · 2022: 69 · 2021: 81 · 2020: 89 · 2019: 154 · 2018: 60 · 2017: 53 · 2016: 49 · 2015: 57 · 2014: 47 · 2013: 49 · 2012: 31
- FWCI
- 36.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA21765, P30CA021765)
- National Institute of General Medical Sciences (U01GM92666, U01GM092666)
- Topics
- Health Sciences › Medicine › Hematology › Methemoglobinemia and Tumor Lysis Syndrome
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Health Sciences › Medicine › Surgery › Muscle and Compartmental Disorders
- Keywords
- tumor lysis syndrome, hematologic malignancies, risk assessment, prophylaxis, treatment, pediatric oncology, emergency management
- MeSH terms
- Child, Humans, Male, Tumor Lysis Syndrome, Risk Assessment, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.